Our Business Units:

Medicine and technology that matters

Equity Pharma Holdings is a privately owned South African-based specialist Pharmaceutical and Medical Technology business.
Equity Pharma Holdings’ mission is to strive for excellence in the marketing of a vitally important and unique range of specialist products that enhance the well-being of thousands of people in the region.


More
Partnership Solutions

News
Expand

  • LINK Healthcare announces agreement with Sanochemia Pharmazeutika AG for regional rights to Secrelux® Read more
  • Gentium To Initiate Clinical Development in Japan and Expand Named-Patient Program Access to Asia and Japan. Read more
  • Colistin-LINK plays significant role in treating superbugs. Read more
  • Australian-based specialist pharmaceutical and medical technologies business, LINK Healthcare today announced a significant expansion of its operations in the 'Triple A' regions of Australasia, Asia and Africa. Read more
  • Link Healthcare & Martindale Pharma Partner to Provide Acetylcysteine Link Injection in Australia. LINK Healthcare (‘LINK’) is pleased to announce that it has recently launched in Australia Acetylcysteine-LINK Injection, for the emergency treatment of paracetamol overdose. Read more
  • Waterford’s EirGen Pharma partners with South African firm.  EirGen Pharma, currently on an Enterprise Ireland trade mission to South Africa, has secured a significant partnership agreement with South African pharmaceuticals company Equity Pharmaceuticals to develop and commercially supply five oncology products from its Waterford facility.  7th November, 2011. Read more
  • LINK Healthcare announces it has been granted a licence to market Relistor® (methylnaltrexone) in Australia, New Zealand, South Africa and Asia from Salix Pharmaceuticals, Inc. of North Carolina, USA. 19th October, 2011. . Read more
  • LINK Pharma has received marketing approval in both Australia and New Zealand for "ANAPEN 500," a 500 microgram adrenaline auto-injector. 29th September, 2011. Read more
  • LINK Pharma has acquired a range of adrenaline products previously sold by Astra Zeneca Australia. 29th June, 2011 . Read more
  • Gentium S.p.A. announced the appointment of LINK Pharmaceuticals as exclusive distributor of Defibrotide in Australia and New Zealand. June 15, 2011. Read more
  • Stallergenes obtains a marketing authorisation for Oralair® in Australia. 18 May, 2011. Read more